Condition | Effectiveness Rating | Mechanism of Action | Typical Dosage Range | Notable Research Findings | |
Irritable Bowel Syndrome (IBS) | Moderate to High | Modulates gut microbiota, reduces inflammation, improves gut motility | 10^8 - 10^10 CFU/day | Studies indicate improvements in abdominal pain, bloating, and bowel movement regularity. | |
Inflammatory Bowel Disease (IBD) | Moderate | Reduces inflammation, strengthens intestinal barrier | 10^9 - 10^11 CFU/day | Research suggests potential in reducing disease activity and improving symptoms. | |
Antibiotic-Associated Diarrhea | High | Restores gut microbiota balance, inhibits pathogen growth | 10^8 - 10^10 CFU/day | Studies show a significant reduction in the incidence and severity of diarrhea. | |
Constipation | Moderate | Improves gut motility, increases stool frequency | 10^9 - 10^10 CFU/day | L. rhamnosus can help regulate bowel movements and alleviate constipation symptoms. | |
Bloating | Moderate | Reduces gas production, improves digestion | 10^9 - 10^10 CFU/day | Research suggests potential in reducing bloating and abdominal discomfort. |
Product Form | CFU Range | Stability Features | Best For | Special Considerations | |
Capsules | 1-100 billion CFU | Shelf-stable, convenient | Daily maintenance, travel | May contain fillers or additives | |
Powders | 1-500 billion CFU | Versatile, easy to mix | Targeted dosages, specific needs | Requires proper storage to maintain potency | |
Specialized Formulas (e.g., Nudora Orange) | Varies | Often includes prebiotics and other supporting ingredients | Addressing specific health concerns (e.g., skin health) | May be more expensive than other forms |